Yousif Capital Management LLC Has $28.34 Million Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Yousif Capital Management LLC reduced its holdings in Intuitive Surgical, Inc. by 1.6%, owning 52,152 shares worth approximately $28.34 million.
• Intuitive Surgical's stock recently experienced a 3.2% decline and currently trades at $429.59, with a 12-month low of $425.00 and a high of $616.00.
• Institutional investors collectively own 83.64% of Intuitive Surgical's shares, with notable increases in holdings from firms like Vanguard Group and Wellington Management in the first quarter.

Yousif Capital Management LLC lessened its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,152 shares of the medical equipment provider's stock after selling 865 shares during the quarter. Yousif Capital Management LLC's holdings in Intuitive Surgical were worth $28,340,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Intuitive Surgical by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider's stock valued at $16,178,258,000 after buying an additional 453,335 shares during the period. Invesco Ltd. increased its holdings in Intuitive Surgical by 1.7% in the 1st quarter. Invesco Ltd. now owns 4,219,974 shares of the medical equipment provider's stock valued at $2,090,027,000 after buying an additional 71,794 shares during the period. Northern Trust Corp increased its holdings in Intuitive Surgical by 0.3% in the 1st quarter. Northern Trust Corp now owns 3,631,281 shares of the medical equipment provider's stock valued at $1,798,465,000 after buying an additional 11,988 shares during the period. Wellington Management Group LLP increased its holdings in Intuitive Surgical by 15.0% in the 1st quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider's stock valued at $1,732,975,000 after buying an additional 457,080 shares during the period. Finally, Nuveen LLC bought a new stake in Intuitive Surgical in the 1st quarter valued at $1,715,899,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Down 3.2%

Shares of NASDAQ ISRG opened at $429.59 on Monday. The firm's 50-day simple moving average is $458.68 and its 200 day simple moving average is $497.84. The company has a market cap of $154.00 billion, a price-to-earnings ratio of 59.91, a price-to-earnings-growth ratio of 4.51 and a beta of 1.61. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm's quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Amy L. Ladd sold 336 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total transaction of $157,956.96. Following the transaction, the director owned 1,074 shares in the company, valued at $504,898.14. This represents a 23.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,224 shares of company stock worth $21,716,492 in the last 90 days. Corporate insiders own 0.70% of the company's stock.

Analyst Ratings Changes

ISRG has been the topic of several analyst reports. The Goldman Sachs Group lowered their price target on shares of Intuitive Surgical from $621.00 to $567.00 and set a "buy" rating on the stock in a report on Wednesday, October 1st. Zacks Research lowered shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $615.00 target price on shares of Intuitive Surgical in a report on Tuesday, August 19th. UBS Group upped their target price on shares of Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a report on Friday, August 22nd. Fourteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $589.43.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.